JASCAYD by Boehringer Ingelheim is 4 (pde4) with at least nine-fold preferential inhibition of the pde4b isoenzyme over pde4a, pde4c, and pde4d based on in vitro data. Approved for idiopathic pulmonary fibrosis (ipf) in adult patients, progressive pulmonary fibrosis (ppf) in adult patients. First approved in 2025.
Drug data last refreshed 13h ago · AI intelligence enriched 1w ago
JASCAYD (nerandomilast) is an oral small-molecule PDE4B-selective inhibitor approved for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) in adults. It works by inhibiting phosphodiesterase 4 (PDE4), which elevates intracellular cAMP and reduces profibrotic growth factors and inflammatory cytokines. The drug offers both antifibrotic and immunomodulatory effects targeting the underlying pathology of progressive fibrotic lung diseases.
Recent launch with moderate competitive pressure (30/100) creates growth opportunities for commercial teams building market presence in IPF/PPF segments.
4 (PDE4) with at least nine-fold preferential inhibition of the PDE4B isoenzyme over PDE4A, PDE4C, and PDE4D based on in vitro data. PDE4 hydrolyzes and inactivates cyclic adenosine monophosphate (cAMP). Nerandomilast exerts both antifibrotic and immunomodulatory effects as PDE4B inhibition…
Worked on JASCAYD at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
JASCAYD is a recently launched specialty pharma asset in a high-value rare disease indication (IPF/PPF), offering early-career professionals opportunities in launch strategy, pulmonology sales, and market access. Team size and career progression will depend on commercial success and Boehringer Ingelheim's investment level in the product.